Clinical Trials Directory

Trials / Completed

CompletedNCT02889068

Targeted Next Generation Sequencing and Intellectual Disability

Status
Completed
Phase
Study type
Observational
Enrollment
40 (actual)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The purpose is to determine the benefit of next generation sequencing (NGS) targeted on genes involved in intellectual disability for etiologic diagnosis of intellectual disabilities. In other words, it concerns the number of patients whose etiologic diagnosis will be established with NGS and could not with common techniques. Actually, the molecular etiology of intellectual disability is crucial to calculate the risk of recurrence and allows the perinatal diagnosis to these families. Secondary purposes are: 1. To determine the place of NGS in the strategy of etiologic diagnosis of intellectual disability, to determine the order of analyses performed for a patient with intellectual disability without clinical signs. 2. To evaluate the number of variants with unknown significance and thus non-usable for genetic counselling without supplementary analysis. 3. To determine the number of samples that can be at most pooled keeping a good efficacy of capture and results with suitable read depth 4. To determine the possibility of detecting copy number variations (CNVs) in genes of interest with NGS 5. To establish genotype/phenotype correlations for each gene for which a mutation has been identified 6. To optimize the software pipelining for a rapid analysis for diagnosis.

Conditions

Interventions

TypeNameDescription
OTHERBlood sample

Timeline

Start date
2015-07-01
Primary completion
2016-09-30
Completion
2017-01-30
First posted
2016-09-05
Last updated
2017-07-28

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02889068. Inclusion in this directory is not an endorsement.